306 related articles for article (PubMed ID: 21270465)
1. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
Pechtl IC; Kavanagh D; McIntosh N; Harris CL; Barlow PN
J Biol Chem; 2011 Apr; 286(13):11082-90. PubMed ID: 21270465
[TBL] [Abstract][Full Text] [Related]
2. Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variations.
Hocking HG; Herbert AP; Kavanagh D; Soares DC; Ferreira VP; Pangburn MK; Uhrín D; Barlow PN
J Biol Chem; 2008 Apr; 283(14):9475-87. PubMed ID: 18252712
[TBL] [Abstract][Full Text] [Related]
3. Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation.
Kerr H; Wong E; Makou E; Yang Y; Marchbank K; Kavanagh D; Richards A; Herbert AP; Barlow PN
J Biol Chem; 2017 Aug; 292(32):13345-13360. PubMed ID: 28637873
[TBL] [Abstract][Full Text] [Related]
4. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.
Hyvärinen S; Meri S; Jokiranta TS
Blood; 2016 Jun; 127(22):2701-10. PubMed ID: 27006390
[TBL] [Abstract][Full Text] [Related]
5. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.
Lehtinen MJ; Rops AL; Isenman DE; van der Vlag J; Jokiranta TS
J Biol Chem; 2009 Jun; 284(23):15650-8. PubMed ID: 19351878
[TBL] [Abstract][Full Text] [Related]
6. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.
Ferreira VP; Herbert AP; Cortés C; McKee KA; Blaum BS; Esswein ST; Uhrín D; Barlow PN; Pangburn MK; Kavanagh D
J Immunol; 2009 Jun; 182(11):7009-18. PubMed ID: 19454698
[TBL] [Abstract][Full Text] [Related]
7. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
Józsi M; Strobel S; Dahse HM; Liu WS; Hoyer PF; Oppermann M; Skerka C; Zipfel PF
Blood; 2007 Sep; 110(5):1516-8. PubMed ID: 17495132
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants.
Dekkers G; Brouwer MC; Jeremiasse J; Kamp A; Biggs RM; van Mierlo G; Lauder S; Katti S; Kuijpers TW; Rispens T; Jongerius I
J Immunol; 2020 Oct; 205(7):1778-1786. PubMed ID: 32848031
[TBL] [Abstract][Full Text] [Related]
9. Comparison of surface recognition and C3b binding properties of mouse and human complement factor H.
Cheng ZZ; Hellwage J; Seeberger H; Zipfel PF; Meri S; Jokiranta TS
Mol Immunol; 2006 Mar; 43(7):972-9. PubMed ID: 16023208
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces.
Dopler A; Stibitzky S; Hevey R; Mannes M; Guariento M; Höchsmann B; Schrezenmeier H; Ricklin D; Schmidt CQ
Front Immunol; 2021; 12():615748. PubMed ID: 33732239
[TBL] [Abstract][Full Text] [Related]
11. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity.
Tortajada A; Montes T; Martínez-Barricarte R; Morgan BP; Harris CL; de Córdoba SR
Hum Mol Genet; 2009 Sep; 18(18):3452-61. PubMed ID: 19549636
[TBL] [Abstract][Full Text] [Related]
12. Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d.
Bhattacharjee A; Lehtinen MJ; Kajander T; Goldman A; Jokiranta TS
Mol Immunol; 2010 May; 47(9):1686-91. PubMed ID: 20378178
[TBL] [Abstract][Full Text] [Related]
13. Use of time-resolved FRET to validate crystal structure of complement regulatory complex between C3b and factor H (N terminus).
Pechtl IC; Neely RK; Dryden DT; Jones AC; Barlow PN
Protein Sci; 2011 Dec; 20(12):2102-12. PubMed ID: 21936007
[TBL] [Abstract][Full Text] [Related]
14. Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R.
Cserhalmi M; Uzonyi B; Merle NS; Csuka D; Meusburger E; Lhotta K; Prohászka Z; Józsi M
Front Immunol; 2017; 8():1800. PubMed ID: 29321782
[TBL] [Abstract][Full Text] [Related]
15. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein.
McRae JL; Duthy TG; Griggs KM; Ormsby RJ; Cowan PJ; Cromer BA; McKinstry WJ; Parker MW; Murphy BF; Gordon DL
J Immunol; 2005 May; 174(10):6250-6. PubMed ID: 15879123
[TBL] [Abstract][Full Text] [Related]
16. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome.
Martínez-Barricarte R; Heurich M; López-Perrote A; Tortajada A; Pinto S; López-Trascasa M; Sánchez-Corral P; Morgan BP; Llorca O; Harris CL; Rodríguez de Córdoba S
Mol Immunol; 2015 Aug; 66(2):263-73. PubMed ID: 25879158
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional characterization of the product of disease-related factor H gene conversion.
Herbert AP; Kavanagh D; Johansson C; Morgan HP; Blaum BS; Hannan JP; Barlow PN; Uhrín D
Biochemistry; 2012 Mar; 51(9):1874-84. PubMed ID: 22320225
[TBL] [Abstract][Full Text] [Related]
18. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome.
Sánchez-Corral P; Pérez-Caballero D; Huarte O; Simckes AM; Goicoechea E; López-Trascasa M; de Córdoba SR
Am J Hum Genet; 2002 Dec; 71(6):1285-95. PubMed ID: 12424708
[TBL] [Abstract][Full Text] [Related]
19. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H.
Hellwage J; Jokiranta TS; Friese MA; Wolk TU; Kampen E; Zipfel PF; Meri S
J Immunol; 2002 Dec; 169(12):6935-44. PubMed ID: 12471127
[TBL] [Abstract][Full Text] [Related]
20. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.
Nilsson SC; Karpman D; Vaziri-Sani F; Kristoffersson AC; Salomon R; Provot F; Fremeaux-Bacchi V; Trouw LA; Blom AM
Mol Immunol; 2007 Mar; 44(8):1835-44. PubMed ID: 17084897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
